Showing results (71-80 of 82) with videos related to
Sort By:
Pageof 9
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytesM J Thomassen, J M Antal, M J Connors, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effectsR M Bukowski, G T Budd, J A Gibbons, et al.Journal of the American Geriatrics Society|May 1, 1985
Relationship in very elderly veterans of nutritional status, self-perceived chewing ability, dental status, and social isolationS R Gordon, S L Kelley, J R Sybyl, et al.Investigational New Drugs|August 25, 2000
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomasT Chidiac, G T Budd, R Pelley, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1996
Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancyT Olencki, J Finke, R Tubbs, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancerG T Budd, P C Adamson, M Gupta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapyR M Bukowski, P Rayman, R Uzzo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findingsR M Bukowski, T Olencki, H Gunn, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 1, 1997
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of responseR M Bukowski, T Olencki, Q Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 1999
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinomaR M Bukowski, P Rayman, L Molto, et al.Pageof 9